Prédicteurs moléculaires et nouvelles cibles en oncologie (PMNCO)

Laboratory presentation

This unit works on the identification and validation of new therapeutic targets as well as molecular predictors in oncology. This work is based on the principle of high-throughput molecular characterization in order to identify therapeutic targets. The mission of this team is to transfer molecular knowledge to clinical practice, and to use patient samples as a source of research hypotheses. One of the objectives is the setting up of clinical trials to test biomarkers, the second is project management or in support of other units performing fondamental research for translational research. Technology development and bioinformatics tools for translational research is one of the objectives of this unit.

The 20 latest publications

Title Authors Publication date Source
eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma A. Moya-Plana, Stéphan Vagner, Caroline Robert 05/01/23 European Journal of Cancer
Erratum: Withdrawal notice to “Structural and functional characterization for interaction of silver nanoparticles with ergostrol in Trichoderma harzianum” [Microb. Pathog. 125 (2018) 318–324, (S0882401018305746), (10.1016/j.micpath.2018.09.039)] Ahsan Z. Rizvi 05/01/23 Microbial Pathogenesis
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma Marie Breckler, Nathalie Droin 04/03/23 Cancer Discovery
Post-transcriptional polyadenylation site cleavage maintains 3′-end processing upon DNA damage Rym Sfaxi, Biswendu Biswas, Galina Boldina, Mandy Cadix, Martin Dutertre, Stéphan Vagner 04/03/23 EMBO Journal
Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency Léa Guerrini-Rousseau 04/01/23 Gastroenterology
Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma Giuseppina Claps, Caroline Robert 03/03/23 Journal for ImmunoTherapy of Cancer
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation Fabrice André 03/01/23 Annals of Oncology
Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist Olivier Lambotte 03/01/23 European Journal of Cancer
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis Francesco Facchinetti 02/01/23 European Journal of Cancer
Facing points of view: Representations on adjuvant endocrine therapy of premenopausal patients after breast cancer and their healthcare providers in France. The FOR-AD study Maria Alice Borinelli-Franzoi, Elise Martin, Antonio Di Meglio, Ines Maria Vaz-Duarte-Luis 02/01/23 European Journal of Oncology Nursing
Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours Thomas Kergrohen, Yassine Ajlil, M. A. Debily 01/01/23 Acta Neuropathologica
Discussion about the presentation: “Metastatic melanoma, immunotherapy and long-term survival: Where do we stand?” Caroline Robert 01/01/23 Bulletin de l'Academie Nationale de Medecine
Spatial patterns of the cap-binding complex eIF4F in human melanoma cells Sara Faouzi, Caroline Robert 01/01/23 Computational and Structural Biotechnology Journal
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial Yohann Loriot 01/01/23 European Urology
Bodywide ecological interventions on cancer Laurence Zitvogel 01/01/23 Nature Medicine
Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer Fabrice André 01/01/23 OncoImmunology
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer Francesco Facchinetti, L. Friboulet, Antoine Hollebecque 12/01/22 Annals of Oncology
Reply to the Letter to the Editor ‘Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification’ by Hannoun-Levi et al. M. A. Franzoi, Fabrice André 12/01/22 Annals of Oncology
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy Jean Charles Soria 12/01/22 European Journal of Cancer
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Alexandra Leary 12/01/22 Gynecologic Oncology

Number of publications of the laboratory by scientific field (2016-2021)

Every paper can be classified in one or more scientific fields. The figure below shows the lab's number of publications in each scientific field, according to the ASJC classification (Elsevier)